Loading...
•
Jun 30, 2020
TherapeuticsMD Q2 2020 Earnings Report
Reported financial results for the second quarter, showing resilience despite the COVID-19 pandemic.
Key Takeaways
TherapeuticsMD reported a net product revenue of $10.7 million for Q2 2020. The company focused on reducing operating expenses and reorienting the sales force. Net loss for the quarter was $52.0 million, or $0.19 per basic and diluted share.
Total net product revenue was $10.7 million despite COVID-19 impacts.
ANNOVERA prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous eight week period.
IMVEXXY new prescriptions increased 33% for the eight weeks ended July 24, 2020 over the previous eight week period.
Operating expenses decreased by $9.2 million to $51.3 million.
Forward Guidance
TherapeuticsMD is focused on driving revenue and achieving its goal of reaching EBITDA break even in 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...